Jun 27, 2018
Dave Domzalski,
CEO, Foamix Pharmaceuticals reminds us that acne is the most common
skin condition affecting 50 million people in the US alone, how
little has changed in the treatment of outbreaks, and how side
effects of commonly prescribed acne treatments often result in many
people discontinuing use leaving their acne unresolved.
Foamix is in late stage development of a topical form of
minocycline, usually prescribed as an oral antibiotic, that is
applied directly to the skin as a foam and that is showing fewer
side-effects and greater impact.
#acne #acneprone #AcneAwareness #skincare #clearskin #dermatology #dermatologist